EUVIMEDEUVIMED entdecken
Vergleichsstudie

Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy

Firas Bahdi iD, Sagar Shah, Fadi Dahoud, Maryam Farooq, Philip Kozan, Stephen Kim, Alireza Sedarat, Na Shen, Adarsh Thaker, Jennifer M Kolb, Erik Dutson, V Raman Muthusamy und 1 weitere

Clinical Obesity · 2025

DOI: 10.1111/cob.70001 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Obesity, 2025. Verfasst von Firas Bahdi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Californi…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Gastrectomy, Gastroplasty, Obesity, Morbid. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Weight recidivism following sleeve gastrectomy (SG) is common. Adjuvant treatments include new glucagon‐like peptide 1 and glucose‐dependent insulinotropic peptide receptor agonists (GLP1/GIP‐RA) or revisional endoscopic sleeve gastroplasty (R‐ESG). We here compare the outcomes of these treatments.

Methods

A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R‐ESG for weight recidivism between January 2019 and 2023 at large academic centre. Primary outcomes were total body weight loss (TBWL) and adverse events (AEs). Secondary outcomes were changes in metabolic parameters. Tertiary outcome was to compare GLP1/GIP‐RA outcomes in SG patients to matched patients with intact stomach.

Results

Our study included 68 (prior SG + GLP1/GIP‐RA) and 22 (prior SG + R‐ESG). R‐ESG offered higher TBWL% than GLP1/GIP‐RA at 3 (11.2% vs. 4.3%, p < .001), 6 (13.5% vs. 6.8%, p < .001) and 12 months (13.4% vs. 9.2%, p = .07) with no significant difference in AEs or change in metabolic parameters. On subgroup analysis, tirzepatide achieved similar 12‐months TBWL% as R‐ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04). Compared to patients with intact stomach ( n = 87), GLP1/GIP‐RA achieved significantly lower TBWL% in patients with prior SG at 3 (4.3% vs. 5.7%, p = .02), 6 (6.8% vs. 9.2%, p = .02) and 12 months (9.2% vs. 12.7%, p = .03). Medication refills were difficult in 41.3% of patients.

Conclusions

In a single‐centre real‐world experience study, R‐ESG and tirzepatide appear to offer more weight loss than semaglutide in SG patients with weight recidivism although GLP1/GIP‐RA were underdosed. GLP1/GIP‐RA achieved higher weight loss in patients with intact stomach than those with prior SG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesGastrectomyGastroplastyObesity, MorbidHumansMaleFemaleRetrospective StudiesAdultMiddle AgedReoperationWeight LossTreatment OutcomeRecurrenceTirzepatideGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

endoscopic sleeve gastroplastysemaglutidesleeve gastrectomytirzepatide

Substanzen

Glucagon-Like PeptidesTirzepatideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Department of Surgery, Section of Minimally Invasive and Bariatric Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Firas Bahdi

Zitieren

APA

Bahdi, F., Shah, S., Dahoud, F., Farooq, M., Kozan, P., Kim, S., Sedarat, A., Shen, N., Thaker, A., Kolb, J. M., Dutson, E., Muthusamy, V. R., & Issa, D. (2025). Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy. Clinical Obesity. https://doi.org/10.1111/cob.70001

Vancouver

Bahdi F, Shah S, Dahoud F, Farooq M, Kozan P, Kim S, et al. Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy. Clinical Obesity. 2025. doi:10.1111/cob.70001

BibTeX
@article{Bahdi2025,
  author = {Bahdi, Firas and Shah, Sagar and Dahoud, Fadi and Farooq, Maryam and Kozan, Philip and Kim, Stephen and Sedarat, Alireza and Shen, Na and Thaker, Adarsh and Kolb, Jennifer M and Dutson, Erik and Muthusamy, V Raman and Issa, Danny},
  title = {Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy},
  journal = {Clinical Obesity},
  year = {2025},
  doi = {10.1111/cob.70001}
}
Kostenlos starten →